Drugs Made In America Acquisition Corp. (DMAAR) Operating Income (2025 - 2026)
Drugs Made In America Acquisition's (DMAAR) quarterly Operating Income came in at -$136934.0 in Q2 2026, down 3.8% on a YoY basis from -$142345.4 in Q2 2025, and up 93.45% quarter-over-quarter from -$2.1 million in Q4 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Operating Income (2025 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Operating Income for 2 consecutive years, with -$136934.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income fell 3.8% year-over-year to -$136934.0; the trailing twelve-month figure through Jun 2026 stood at -$2.6 million (changed N/A YoY), and the FY2025 full-year result was -$2.8 million, down 906.28% from the prior year.
- Operating Income climbed to -$136934.0 in Q2 2026 per DMAAR's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$131919.0 in Q2 2025 and bottomed at -$2.1 million in Q4 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -136,934.00 |
| Dec 31, 2025 | -2.09 Mn |
| Sep 30, 2025 | -263,703.00 |
| Jun 30, 2025 | -131,919.00 |
| Mar 31, 2025 | -330,925.00 |